Skip to main content
MRVI logo

MRVI · Maravai Lifesciences Holdings, Inc.

Track MRVI — free
$5.70 -0.08 (-1.38%) At close · Aug 14
Market Cap
$1.48B
Shares
259.67M

Maravai Lifesciences Holdings, Inc. Earnings Call Transcripts

Every quarterly earnings call for Maravai Lifesciences Holdings, Inc. (MRVI) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-06
Q2 2026 Maravai LifeSciences Earnings Conference Call
Confident tone TriLink mRNA Growth ModTail Adoption Commercial Execution
Revenue
$51.44M
▲ 8.5% YoY
Diluted EPS
$-0.08
Gross margin
40.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference in New York
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Maravai Lifesciences Holdings, Inc. Q1 FY2026 Earnings Call
Confident tone TriLink revenue growth Cygnus performance ModTail adoption
Revenue
$65.84M
▲ 40.5% YoY
Diluted EPS
$-0.02
Gross margin
51.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Maravai Lifesciences Holdings, Inc. Q4 FY2025 Earnings Call
Confident tone 2026 guidance and outlook Adjusted EBITDA recovery Trilink commercial execution and CleanCap
Revenue
$49.87M*
▼ 11.8% YoY
Gross margin
25.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Maravai Lifesciences Holdings, Inc. Q3 FY2025 Earnings Call
Positive tone Nucleic Acid Products / TriLink Recovery Product Innovation and Launches Cost Restructuring and EBITDA Improvement
Revenue
$41.63M
▼ 39.7% YoY
Diluted EPS
$-0.18
Gross margin
13.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Maravai Lifesciences Holdings, Inc. Q2 FY2025 Earnings Call
Positive tone Nucleic Acid Production (NAP) / mRNA headwinds Path back to profitability CDMO business
Revenue
$47.40M
▼ 31.7% YoY
Diluted EPS
$-0.27
Gross margin
16.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Maravai Lifesciences Holdings, Inc. Q1 FY2025 Earnings Call
Positive tone China / BST export exposure Tariffs and supply chain mitigation Guide RNA / oligo and Molecular Assemblies integration
Revenue
$46.85M
▼ 27% YoY
Diluted EPS
$-0.21
Gross margin
16.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Maravai Lifesciences Holdings, Inc. Q4 FY2024 Earnings Call
Cautious tone High-volume CleanCap demand and customer inventory New product launches (CleanScribe, etc.) Flanders 2 facility and commercial pipeline
Revenue
$56.56M*
▼ 23.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Maravai Lifesciences Holdings, Inc. Q3 FY2024 Earnings Call
Cautious tone Nucleic Acid Production (NAP) segment Cost structure and commercial investment Biologics Safety Testing (BST) softness
Revenue
$69.03M
▲ 3.2% YoY
Diluted EPS
$-0.68
Gross margin
46.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Maravai Lifesciences Holdings, Inc. Q2 FY2024 Earnings Call
Positive tone Flanders facility ramp-up Margin and pricing dynamics New product introductions (NPI)
Revenue
$69.42M
▲ 0.7% YoY
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Maravai Lifesciences Holdings, Inc. Q1 FY2024 Earnings Call
Positive tone Nucleic Acid Production product innovation Return to growth strategy and commercial team Q1 financial results and cash position
Revenue
$64.18M
▼ 18.8% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Maravai Lifesciences Holdings, Inc. Q4 FY2023 Earnings Call
Positive tone CleanCap pipeline expansion Nucleic Acid Production segment Biologics Safety Testing segment
Revenue
$74.14M*
▼ 63.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Maravai Lifesciences Holdings, Inc. Q3 FY2023 Earnings Call
Revenue
$66.86M
▼ 65% YoY
Diluted EPS
$-0.05
▼ 114.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Maravai Lifesciences Holdings, Inc. Q2 FY2023 Earnings Call
Revenue
$68.91M
▼ 71.6% YoY
Diluted EPS
$-0.05
▼ 109.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Maravai Lifesciences Holdings, Inc. Q1 FY2023 Earnings Call
Revenue
$79.03M
▼ 67.7% YoY
Diluted EPS
$0.00
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Maravai Lifesciences Holdings, Inc. Q4 FY2022 Earnings Call
Revenue
$204.71M*
▼ 10.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Maravai Lifesciences Holdings, Inc. Q3 FY2022 Earnings Call
Revenue
$191.26M
▼ 6.6% YoY
Diluted EPS
$0.34
▼ 22.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Maravai Lifesciences Holdings, Inc. Q2 FY2022 Earnings Call
Revenue
$242.73M
▲ 11.5% YoY
Diluted EPS
$0.53
▲ 20.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Maravai Lifesciences Holdings, Inc. Q1 FY2022 Earnings Call
Revenue
$244.29M
▲ 64.8% YoY
Diluted EPS
$0.50
▲ 108.3% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Maravai Lifesciences Holdings, Inc. Q4 FY2021 Earnings Call
Revenue
$228.44M*
▲ 132.3% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Maravai Lifesciences Holdings, Inc. Q3 FY2021 Earnings Call
Revenue
$204.81M
▲ 133.1% YoY
Diluted EPS
$0.44
▲ 266.7% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Maravai Lifesciences Holdings, Inc. Q2 FY2021 Earnings Call
Revenue
$217.78M
▲ 364.3% YoY
Diluted EPS
$0.44
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Maravai Lifesciences Holdings, Inc. Q1 FY2021 Earnings Call
Revenue
$148.21M
▲ 190.7% YoY
Diluted EPS
$0.24
▲ 166.7% YoY
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-02
Maravai Lifesciences Holdings, Inc. Q4 FY2020 Earnings Call
Revenue
$98.35M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 earnings calls
Key facts CIK 1823239 CUSIP 56600D107 13F (30d) 177 filings 173 filers Visit website Investor relations